CRISPR Therapeutics: The Gene-Editing Opportunity You'll Regret Overlooking at These Valuations

Recent quarterly earnings from Vertex Pharmaceuticals (NASDAQ: VRTX) have captured investor attention with improved projections for Casgevy sales. However, savvy long-term investors should focus on the company that truly developed this breakthrough treatment—CRISPR Therapeutics (NASDAQ: CRSP)—which remains substantially undervalued despite holding the keys to gene-editing’s future.

The landscape for gene-editing therapeutics is shifting dramatically. Casgevy, the first CRISPR-based therapy approved by the FDA, represents validation that this transformative technology can deliver real clinical results for patients with severe genetic disorders. Vertex profits from the commercial partnership, but CRISPR Therapeutics, headquartered in Switzerland, originated the science behind this breakthrough and stands to capture enormous value as adoption accelerates.

Casgevy’s Commercial Trajectory Creates Foundation for Growth

Vertex recently announced stronger 2026 sales expectations for Casgevy, which treats sickle cell disease and beta thalassemia. The Boston-based biotech, which dominates cystic fibrosis treatment with marketed drugs like Kalydeco, Trikafta, and Orkambi, continues expanding its revenue base. Yet investors fixating on Vertex miss the larger opportunity.

CRISPR Therapeutics will directly benefit from growing Casgevy adoption, generating revenue that funds its deeper pipeline of gene-editing candidates. Unlike companies selling incremental improvements to existing drug categories, CRISPR operates in a space where individual therapies can command extraordinary prices—Casgevy’s $2.2 million per-patient price tag reflects the genuine value these functional cures deliver.

The Real Prize: A Clinical Pipeline with Blockbuster Potential

This is where CRISPR Therapeutics’ competitive advantage becomes evident. The company has successfully demonstrated it possesses the scientific foundation and manufacturing infrastructure to deliver gene-editing therapies. With five clinical-stage candidates advancing through development, each addresses larger potential patient populations than sickle cell disease.

CTX310 stands out as particularly compelling—a single-treatment cardiovascular therapy that demonstrated capacity to reduce triglycerides and LDL cholesterol by more than 80% in trials. This single program, if successful, could generate billions in annual revenue given the prevalence of dyslipidemia in aging populations worldwide.

Additional candidates include CTX320 for atherosclerotic cardiovascular disease, CTX211 designed to restore insulin production in type 1 diabetes patients, and the anticoagulant SRSD107 (developed with partner Sirius Therapeutics) targeting thrombosis. Each represents a meaningful commercial opportunity in massive disease categories where current treatments remain suboptimal.

Navigating the Profitability Challenge with Substantial Capital

CRISPR Therapeutics remains unprofitable, which explains why shares have declined 64% over the past five years. The company reported $3.5 million in 2025 revenue (down 91% year-over-year due to an accounting adjustment involving collaboration agreements) and a net loss of $6.47 per share compared to $4.34 per share in 2024.

However, the balance sheet tells a different story. The company maintains over $1.9 billion in cash reserves—substantial capital to advance multiple programs simultaneously without immediate pressure to achieve profitability. As Casgevy revenues expand, the company can accelerate spending on its most promising candidates.

This financial runway is critical because the long-term value of CRISPR Therapeutics derives from pipeline success rather than near-term earnings. The company’s approach to functional cures—rather than disease management—makes traditional valuation metrics difficult to apply. When successful, these therapies can provide permanent remission or restoration of normal biological function, justifying premium pricing and capturing enormous shareholder value.

Why Institutional Investors Are Taking Notice

Cathie Wood’s Ark Innovation ETF (NYSEMKT: ARKK) maintains approximately 6.3% of assets in CRISPR Therapeutics, ranking it the fund’s second-largest holding after Tesla. This positioning reflects confidence that gene-editing therapies represent transformative technology with decade-long adoption curves ahead.

CRISPR Therapeutics has already proven its scientific credibility and operational capacity. The combination of Casgevy success, a robust clinical pipeline, manufacturing expertise, and substantial capital resources creates conditions for sustained value creation. Additionally, the company’s assets make it an attractive acquisition target for larger pharmaceutical companies seeking entry into gene-editing, providing a potential liquidity event beyond organic pipeline development.

The Investment Case and Important Caveats

At present depressed valuations, CRISPR Therapeutics offers compelling risk-reward asymmetry for patient investors. The company’s current stock price has been pressured by near-term unprofitability and clinical trial execution risks—legitimate concerns. The biotech sector remains inherently volatile, and individual pipeline programs may face regulatory setbacks or clinical trial disappointments.

However, the combination of validated science (FDA approval of Casgevy), deepening cash generation from commercial sales, multiple pipeline shots on goal, manufacturing infrastructure already in place, and substantial cash reserves creates an exceptional opportunity for those with appropriate time horizons. Investors who recognize that gene-editing technology is entering its growth phase early may find they regretted passing on CRISPR Therapeutics at these accessible prices.